RS
PYXS icon

R Squared’s Pyxis Oncology PYXS Stock Holding History

R Squared’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-880
Closed -$1.37K – 1199
2024
Q4 		$1.37K Buy
+880
New +$2.54K ﹤0.01% 1499

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

R Squared's PYXS Position: Q1 2025 in Review

R Squared sold out of Pyxis Oncology (PYXS) in Q1 2025, closing a stake of 880 shares — an estimated $1.37K sold.

R Squared first reported a position in PYXS in Q4 2024 and held it in 1 quarter. The position peaked at $1.37K in Q4 2024. 88 funds tracked by Wall St. Rank hold PYXS as of Q1 2025.

  • R Squared reported no remaining Pyxis Oncology position as of Q1 2025 after selling out during the quarter.
  • R Squared sold 880 Pyxis Oncology shares in Q1 2025, an estimated $1.37K.
  • R Squared first reported a position in Pyxis Oncology in Q4 2024 and held it in 1 quarter.
  • R Squared's Pyxis Oncology position peaked at $1.37K in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.